



# Chronic Lymphocytic Leukemia

- Most common leukemia
- Usual age > 50 yrs
- Increased proliferation and progressive accumulation of neoplastic, immunologically incompetent, clonal lymphocytes
  - -B cell origin > 99%

# Clinical Features of CLL

- · Highly variable presentation
  - Asymptomatic, or vague, non-specific complaints
  - Recurrent infection 10% (often pneumococcus)
- Signs
  - Lymphadenopathy (60%)
  - Splenomegaly (50%)
  - Hepatomegaly (< 40%)





#### Immunological Abnormalities in CLL

- Disturbed Ab production
  - Hypogammaglobulinemia (50%) → bacterial infection
  - Monoclonal Ig paraprotein in serum (10%)
  - Autoantibodies (10%)
- · Minor impairments in cell-mediated immunity
- · Neoplastic lymphocytes
  - Monoclonal surface Ig
  - Abnormal response to Ig challenge

### Clinical Features of CLL

- Laboratory
  - blood and marrow lymphocytosis
  - B cell monoclonality:
     κ vs λ surface light chain
    - single Ig gene rearrangement
  - hypoimmunoglobulinemia
- Prognosis
  - Mean survival = 50-60 months
  - Range = few months to > 20 yrs

# Complications of CLL

## Rai Staging System for CLL

#### Classical Diagnostic Features of Myeloma

- Plasmacytosis in marrow
- Monoclonal protein in serum or urine
- Lytic disease of bone

### Treatment of CLL


- No evidence that therapy prolongs survival
- · Asymptomatic: watch and wait
- Symptomatic:
  - Radiation for local complications
  - Chemotherapy: fludarabine, alkylators, combinations
  - Monoclonal antibodies (eg, Campath)
  - Stem cell transplantation


#### Marrow Plasmacytosis in Myeloma


- Plasma cells > 10%
- · Usually much higher
- · Often present in 'sheets'
- Alternatively, biopsy-proven plasmacytoma
- Other causes of plasmacytosis:
   inflammation, cirrhosis, AIDS


#### Multiple Myeloma


- · Clonal malignancy of plasma cells
- · Increasing incidence
- Blacks:whites 2:1
- Age range 20-100 yrs (peak age 70 yrs)
- Cause unknown (Environmental/Genetic factors)

























#### Diagnosis of Myeloma: Monoclonal Proteins


- 75-80% have serum monoclonal Ig (M-component, paraprotein, or 'spike' on electropheresis)
- 10-20% make light chains only → rapid renal excretion → no paraprotein on serum protein electropheresis
- Non-secretory myeloma rare (< 1%)
- Other causes of monoclonal proteins


   (eg, CLL, lymphoma, benign monoclonal gammopathy)















# Bone Disease in Myeloma

- Unbalanced osteoclast activity
- Radiographic manifestations
   Osteoporosis almost invariable
   Usually multiple lytic lesions
   Axial skeleton involved (active marrow)
   Osteoblastic reaction minimal
- Hypercalciuria and hypercalcemia













# **Benign Monoclonal Gammopathy**

- · Monoclonal Ig as isolated finding
- More common than myeloma
- · No bone disease, anemia, renal dysfunction
- · Most remain stable
- About 10% eventually develop classical myeloma





## Myeloma at Presentation


- Early asymptomatic, incidental diagnosis Paraprotein on electropheresis Mild marrow plasmacytosis Solitary plasmacytoma (10% of cases)
- Late symptomatic
   Bone pain (usually lower back)
   Pneumococcal infection
   Systemic symptoms (eg, weakness, weight loss)
   Related to anemia, renal failure, hypercalcemia


# **Hyperviscosity Syndrome**

- Due to aggregating paraprotein
- · Pathogenesis
  - Circulatory insufficiency, abnormal hemostasis
- Manifestations
  - Bleeding
  - Dyspnea (congestion on CXR)
  - Encephalopathy and visual disturbances









## Immunological Features of Myeloma

- Monoclonal Ig and/or monoclonal light chain
- ↓Levels of normal Ig's (hypogammaglobulinemia)
- Cellular immune responses usually preserved
- Bacterial infections common Early: S pneumoniae

Late: S aureus, Gram negative rods

## Amyloidosis in Myeloma

- Due to light chain deposition in tissues
- Incidence:  $\lambda$  amyloid  $> \kappa$  amyloid
- Organs commonly involved:

Skin


Tongue and GI

Heart


Peripheral nerves


Kidneys Soft tissues


• No effective therapy, except ?stem cell transplant














## Therapy for Myeloma

- Biphosphonates (pamidronate, zoledronate)
- Radiotherapy
- Corticosteroids and conventional chemotherapy
- Thalidomide (anti-angiogenesis)
- Bortezomib (proteasome inhibitor)
- Stem cell transplantation